Perioperative stromal depletion by PEGPH20 in pancreatic ductal adenocarcinoma.

被引：0
|
作者：
Ko, Andrew H.
Cinar, Pelin
Tempero, Margaret A.
Nakakura, Eric K.
Yeh, Benjamin M.
Chondros, Dimitrios
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Pancreas Ctr, San Francisco, CA 94143 USA
[5] Halozyme Therapeut, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps476
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS476
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effect of metformin on survival in pancreatic ductal adenocarcinoma.
    Amin, Sunil
    Mhango, Grace
    Lin, Jenny J.
    Aronson, Anne
    Boffetta, Paolo
    Wisnivesky, Juan P.
    Lucas, Aimee
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [22] Resolving and Targeting the Mechanobiome of Pancreatic Ductal Adenocarcinoma.
    Surcel, A.
    Zhu, Q.
    Schiffhauer, E.
    Anders, R. A.
    Robinson, D. N.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26
  • [23] A novel RAS inhibitor for pancreatic ductal adenocarcinoma.
    Arshad, Tariq
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16263 - E16263
  • [24] Impact of site of metastases in pancreatic ductal adenocarcinoma.
    Arshad, Adeel
    Zhao, Songzhu
    Wei, Lai
    Stephens, Julie
    Manne, Ashish
    Noonan, Anne M.
    Rahman, Shafia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 708 - 708
  • [25] Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis.
    Yu, Kenneth H.
    Mantha, Simon
    Tjan, Catherine
    Kaufmann, Erica S.
    Brenner, Robin
    Lowery, Maeve Aine
    Ku, Geoffrey Yuyat
    Raj, Nitya Prabhakar
    Shcherba, Marina
    Goldberg, Zoe
    Li, Jia
    Zervoudakis, Alice
    Hamilton, Audrey M.
    Won, Elizabeth
    Ucar, Antonio
    Do, Richard K. G.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [26] Characterization of the cachexia pathway in pancreatic ductal adenocarcinoma.
    Ashouri, Karam
    Baca, Yasmine
    Xiu, Joanne
    Soni, Shivani
    Algaze, Sandra
    Jayachandran, Priya
    Wong, Alexandra
    Yang, Yan
    Torres-Gonzalez, Lesly
    Lo, Jae Ho
    Zhang, Wu
    Khushman, Moh'd M.
    Weinberg, Benjamin Adam
    Goel, Sanjay
    Lou, Emil
    Battaglin, Francesca
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 699 - 699
  • [27] PCRT16-001: Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic ductal adenocarcinoma (mPDA)
    Chiorean, E. Gabriela
    Ritch, Paul S.
    Zhen, David Bing
    Poplin, Elizabeth
    George, Ben
    Hendifar, Andrew Eugene
    Dragovich, Tomislav
    Coveler, Andrew L.
    Stoll-D'Astice, Amy C.
    Edwards, Stephanie
    Rosenthal, Adam
    Thorsen, Shelley M.
    Hingorani, Sunil R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [28] Efficacy and Safety of PEGPH20 in Pancreatic Cancer: Systematic Review and Meta-analysis
    Solipuram, Vinod
    Gopalakrishna, Harish
    Naira, Gayatri
    Mohan, Akhila
    CURRENT CANCER THERAPY REVIEWS, 2021, 17 (04) : 255 - 260
  • [29] Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).
    Hingorani, Sunil R.
    Bullock, Andrea J.
    Seery, Tara Elisabeth
    Zheng, Lei
    Sigal, Darren
    Ritch, Paul S.
    Braiteh, Fadi S.
    Zalupski, Mark
    Bahary, Nathan
    Harris, William Proctor
    Pu, Jie
    Aldrich, Carrie
    Khelifa, Sihem
    Wu, Xionghua W.
    Baranda, Joaquina
    Jiang, Ping
    Hendifar, Andrew Eugene
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)
    Hingorani, S. R.
    Bullock, A.
    Seery, T.
    Zheng, L.
    Sigal, D.
    Ritch, P. S.
    Braiteh, F. S.
    Zalupski, M.
    Bahary, N.
    Harris, W.
    Pu, J.
    Aldrich, C.
    Khelifa, S.
    Wu, W.
    Chondros, D.
    Jiang, P.
    Hendifar, A.
    ANNALS OF ONCOLOGY, 2017, 28
12345